FDA Reclassification Paves Regulatory Pathway for Invibio PEEK-OPTIMA[™] Spinal Rods

AUTHOR: Craig Valentine – Invibio Biomaterial Solutions

Request for Reclassification

Until recently, posterior spinal rods and rigid pedicle screw systems, fell under the FDA Order 522 for Class III devices. Class III devices are considered "highest risk" and must follow the FDA's most stringent regulatory pathway, which requires a vigorous Premarket Application (PMA). Class III devices require a robust and completely independent clinical history not based on predicate devices, and therefore can lengthen the time and cost to market.

Invibio Biomaterial Solutions, along with other medical device manufacturers, were requested to submit to the order to reclassify spinal rods and rigid pedicle screw systems, supporting a modification to allow semi-rigid spinal rods to remain Class II devices.

Clinical and biomechanical evidence from over 51,000 PEEK Rod implantations was submitted in support of reclassifying PEEK-OPTIMA Spinal Rods as a Class II device. Class II devices, like Class III devices, require general and special controls that ensure compliance with the FDA's best quality and manufacturing processes, proper labeling and reporting, and adherence to other FDA-imposed special controls that ensure device safety and effectiveness. However, in lieu of the very involved PMA process, Class II devices typically follow the Premarket Notification 510(k) pathway, which provides a much clearer and timely route to market.

Substantial evidence indicated PEEK-OPTIMA Rods were technologically and physically similar to other Class II rigid pedicle systems, not the Class III dynamic stabilization system devices, in which the device had previously been grouped. As a result of the device design and material properties, PEEK-OPTIMA Rods maintain interpedicular distance, eliminating compression and elasticity often found in Class III dynamic stabilization systems. Furthermore, the predominant indication for use as an adjunct to spinal fusion, not dynamic stabilization, offered a new context for reclassification. Several clinical publications have reported high fusion rates, low reoperation rates due to adjacent segment disease and good to excellent clinical outcome scores with PEEK Rods.¹⁻⁵

FDA Reclassification Ruling

The FDA issued a final ruling on December 29, 2016, crediting all stakeholders who contributed to this effort.

Under the final ruling:

 Pedicle screw systems, including PEEK-OPTIMA polymer-based rods, when used as an adjunct to spinal fusion procedures are:

- a. Reclassified from Class III to Class II devices.
- b. Renamed "thoracolumbosacral pedicle screw systems."
- 2. Dynamic stabilization systems, when used as an adjunct to fusion are:
 - a. Reclassified from Class III to Class II devices with special controls.
 - b. Renamed "semi-rigid systems". PEEK-OPTIMA polymer-based rods are included in this sub-type.
- Thoracolumbosacral pedicle screw systems will be more precisely defined to delineate between rigid and semirigid systems.

The FDA also indicated that device technology, like Invibio PEEK-OPTIMA Rods, could fit the new semi-ridged system product class, but would require clinical performance data supporting clear and adequate technological evaluation. Data would need to be representative of design and footprints, correspond to the product being submitted for FDA 510(k) clearance, and along with other Class II general and special controls, provide a reasonable assurance of semi-rigid system safety and effectiveness.

Under the reclassification, manufacturers of current marketed semi-rigid systems, for all indications for use, must submit a 510(k) amendment and comply with rulingdefined special controls by June 30, 2019. To that end, Invibio will enlist a sponsor to assist with obtaining 510(k) clearances for its newly named Class II device, the PEEK-OPTIMA Spinal Rods for spinal lumbar fusion.

The FDA also suggested a continued industry-wide collaboration in eventually removing the clinical data requirement. Doing so would make the 510(k) clearance for Class II semi-rigid devices even more timely and efficient, and foster further technological innovation. That's good news for manufacturers and patients alike.

Why Metal Rod Alternatives Are Necessary

Spinal rods composed of metal are not without challenges, including, but not limited to, rod breakage, screw loosening, and accelerated degeneration at adjacent spinal segments. The high stiffness inherent in all-metal constructs is believed to contribute to these clinical challenges and negatively impact patient outcomes.⁶⁻⁷ In addition, metals like titanium lack artifact-free imaging, which impacts a surgeon's ability to assess posterior decompression and fusion post-operatively.

Semi-Rigid Rods May Bridge Treatment Gap

PEEK-OPTIMA Spinal Rods offer a polymer-based stabilization. The material exhibits sufficient strength to reduce the range of motion⁷⁻⁸ and stabilize the treated segment.⁹ And, with a modulus similar to cortical bone, PEEK still permits physiological movement on adjacent upper and lower segments.⁸ As a result, clinical results increasingly suggest that PEEK-OPTIMA Spinal Rod components preserve or slow down the degeneration of adjacent discs.³ Consequently, patients may benefit from improved load sharing that encourages fusion,^{7,10-11} and more physiologic loading at adjacent levels, which may decelerate degeneration.^{1,12}

ABOUT THE AUTHOR

Craig Valentine

Craig Valentine is the Director of Quality and Regulatory Affairs for Invibio Biomaterial Solutions. Having graduated from the University of Wales at Cardiff in Polymer Chemistry and Technology, Craig moved to the United States,



where he spent 12 years in various technical and R&D roles. In 2007 he moved back to his native England to join Invibio. In his present role, Craig oversees Quality Assurance, Compliance and accreditation for Invibio. In addition, he leads the global RA support team and all product registration activities.

Further information on the final ruling can be found at <u>"Orthopedic Devices; Reclassification of Pedicle Screw Systems,</u> <u>Henceforth To Be Known as Thoracolumbosacral Pedicle Systems, Including Semi-Rigid Systems."</u>

For more information on Invibio PEEK-OPTIMA Rods, please visit https://invibio.com/

REFERENCES

- 1. De lure, F., et al. (May 2012). Posterior lumbar fusion by peek rods in degenerative spine: preliminary report on 30 cases. Eur Spine J, 21(1), 50-54.
- Qi L., etc. (2013). Comparative effectiveness of PEEK rods versus titanium alloy rods in lumbar fusion: a preliminary report. Acta Neurochir (Wein), 155(7), 1187-1193.
- Athanasakopoulos, M, et al. (July 2013) Posterior Spinal Fusion Using Pedicle Screws. ORTHOPEDICS. 36(7), e951-e957. doi:10.3928/01477447-20130624-28.
 Galler, R.M. and Fiore, S. (2014) Retrospective Case Series Review of the Safety and Tolerability of Implanted Polyetheretherketone PEEK Rods. Poster session
- presented at the 2014 Congress of Neurological Surgeons Annual Meeting, Boston, MA.
- 5. Colangeli, S., et al. (June 2015) Polyetheretherketone (PEEK) rods: short-term results in lumbar spine degenerative disease. Journal of neurosurgical sciences, 59(2), 91-96.
- 6. Highsmith, JM, et al. (January 2007). Flexible rods and the case for dynamic stabilization. Neurosurgical Focus, 22(1), 1-5.
- 7. Gornet, MF, et al. (2011). Biomechanical Assessment of a PEEK Rod System for Semi-Rigid Fixation of Lumbar Fusion Constructs. Journal of Biomechanical Engineering, 133(8), 1-12.
- 8. Ponnappan, RK, et al. (March 2009). Biomechanical evaluation and comparison of polyetheretherketone rod system to traditional titanium rod fixation. *The Spine Journal*, 9(3), 263-267.
- 9. Turner, JL, et al. (October 2010). The Mechanical Effect of Commercially Pure Titanium and Polyetheretherketone Rods on Spinal Implants at the Operative and Adjacent Levels. *Spine*, 35(21), E1076-E1082.
- 10. Moumene, M., et al. (2008). Biomechanical Advantages of EXPEDIUM™ PEEK Rods. DePuy Spine, Inc., Raynham, MA.
- 11. Galbusera, F., et al. (2010). Rigid and Flexible Spinal Stabilization Devices: A Biomechanical Comparison. Medical Engineering & Physics, 33, 490-496.
- 12. Ormond, DR, et al. Polyetheretherketone (PEEK) rods in lumbar spine degenerative disease: a case series. J Spinal Disord Tec, 12(8), 693-701.

Copyright ©2017 Invibio Ltd. INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. All rights reserved.



Invibio Ltd.

Victrex Technology Centre Hillhouse International Thornton-Cleveleys Lancashire FY5 4QD, UK

Tel: +44 (0) 1253 898 000

FAX: +44 (0) 1253 898 001

Invibio Inc. 300 Conshohocken State Road West Conshohocken, PA 19428 USA Toll Free: 866-INVIBIO (468-4246) Tel: (484) 342-6004 Fax: (484) 342-6005

For further information please email us at info@invibio.com or visit our website at:

Invibio.com

Victrex plc and/or its group companies ("Victrex plc") believes that the information in this document is an accurate description of the typical characteristics and/or uses of the product or products, but it is the customer's responsibility to thoroughly test the product in each specific application to determine its performance, efficacy, and safety for each end-use product, device or other application. Suggestions of uses should not be taken as inducements to infringe any particular patent. The information and data contained herein are based on information we believe reliable. Mention of a product in this document is not a guarantee of availability.

Victrex plc reserves the right to modify products, specifications and/or packaging as part of a continuous program of product development. Victrex plc makes no warranties, express or implied, including, without limitation, a warranty of fitness for a particular purpose or of intellectual property non-infringement, including, but not limited to patent non-infringement, which are expressly disclaimed, whether express or implied, in fact or by law.

Further, Victrex plc makes no warranty to your customers or agents, and has not authorized anyone to make any representation or warranty other than as provided above. Victrex plc shall in no event be liable for any general, indirect, special, consequential, punitive, incidental or similar damages, including without limitation, damages for harm to business, lost profits or lost savings, even if Victrex has been advised of the possibility of such damages regardless of the form of action.

Supporting information is available on request for all claims referenced in this document.

Copyright ©2017 Invibio Ltd. INVIBIO[™], JUVORA[™] PEEK-OPTIMA[™], INVIBIO BIOMATERIAL SOLUTIONS[™] are trademarks of Victrex plc or its group companies. All rights reserved.